v3.26.1
Revenue
 12 Months Ended
Dec. 31, 2025
Revenue [Abstract]  
REVENUE

17. REVENUE

 

For the years ended December 31, 2025, 2024 and 2023, the Company’s revenue was all recognized at point of time.

 

Revenue for the year ended December 31, 2025, consists of the following:

 

   Corporate
Customers		   Retail
Customers		   Total 
Medical and related products  $280,719   $55   $280,774 
Drugs   209,025    14,400    223,425 
Beauty products   49,841    70    49,911 
Contact lenses   35,000    
—
    35,000 
Nutritional products   5,000    234    5,234 
Supplements   2,405    68    2,473 
Total  $581,990   $14,827   $596,817 

 

The Company operates in multiple geographic regions. Net revenues by geographic area for the period are as follows:

 

Net Revenues by Geographic Area

 

Geographic Area  Net
Revenues		 
United States  $35,000 
Taiwan   561,817 
Total  $596,817 

 

The United States revenues are derived from contact lens sales, while all other product categories, including drugs, medical and related products, nutritional products, and supplements, are sold in Taiwan.

 

Revenue for the year ended December 31, 2024, consists of the following:

 

   Corporate
Customers		   Retail
Customers		   Total 
Drugs  $143,633   $
—
   $143,633 
Medical and related products   292,609    249    292,858 
Nutritional products   41,458    314    41,772 
Supplements   24,057    8,040    32,097 
Total  $501,757   $8,603   $510,360 

 

All product categories are sold in Taiwan for the year ended December 31, 2024.

 

Revenue for the years ended December 31, 2023, consists of the following:

 

   Corporate
Customers		   Retail
Customers		   Total 
Drugs  $141,947   $
—
   $141,947 
Medical and related products   146,593    257    146,850 
Nutritional products   5,934    3,606    9,540 
Supplements   32,341    19,453    51,794 
Total  $326,815   $23,316   $350,131 

 

All product categories are sold in Taiwan for the year ended December 31, 2023.